What is DayTwo?
DayTwo provides personalized nutrition plans and actionable insights designed to help individuals maintain target blood glucose levels and live healthier lives. The company's approach is rooted in studying individual biometrics and lifestyle patterns. The core of DayTwo's program is based on extensive research conducted at the Weizmann Institute of Science in Israel by Prof. Eran Segal and Prof. Eran Elinav. This foundational research technology was licensed to DayTwo upon its completion, with the company being established in 2015 to commercialize these findings. DayTwo operates within the burgeoning digital health and personalized medicine markets, leveraging data science to offer tailored health solutions.
How much funding has DayTwo raised?
DayTwo has raised a total of $85.4M across 6 funding rounds:
Series A
$12M
Series B
$31M
Other Financing Round
$5M
Debt
$150K
Debt
$254K
Unspecified
$37M
Series A (2017): $12M with participation from Johnson & Johnson and Seventure Partners
Series B (2019): $31M led by aMoon, Johnson & Johnson, Ofek Ventures, and Seventure Partners
Other Financing Round (2019): $5M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $254K backed by PPP
Unspecified (2021): $37M with participation from Poalim Capital Markets, La’maison Fund, and Micron Ventures
Key Investors in DayTwo
aMoon
aMoon is an investment firm that focuses on the healthcare and life sciences sectors, likely providing strategic capital for companies advancing medical innovation.
Johnson & Johnson
Johnson & Johnson is a global leader in healthcare, investing in companies that align with their broad portfolio of pharmaceutical, medical device, and consumer health products.
Seventure Partners
Seventure Partners is a venture capital firm specializing in life sciences and digital technologies, actively supporting innovative companies in health and nutrition.
What's next for DayTwo?
With the recent major strategic investment, DayTwo is poised for significant expansion. The company's focus on personalized nutrition, backed by scientific research and substantial capital, positions it to further develop its platform and broaden its market reach. Future initiatives are likely to involve enhancing its data analytics capabilities, expanding its service offerings to address a wider range of health conditions, and forging new partnerships within the healthcare and wellness industries. This strategic financing will be crucial for scaling operations and solidifying DayTwo's position as a leader in data-driven health management.
See full DayTwo company page
